Skip to main content

Drug Interactions between burosumab and Fleet EZ-Prep

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

sodium phosphate burosumab

Applies to: Fleet EZ-Prep (sodium biphosphate / sodium phosphate) and burosumab

CONTRAINDICATED: Concomitant use of burosumab with oral phosphate and/or active vitamin D analogs may increase the risk of hyperphosphatemia and hypervitaminosis D due to additive pharmacologic effects. Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis.

MANAGEMENT: Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment. Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment. Some authorities advise that, if necessary, vitamin D replacement or supplementation with inactive forms of vitamin D may be started or continued as per local guidelines and under serum calcium and phosphate monitoring.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2018) "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical
Major

sodium biphosphate burosumab

Applies to: Fleet EZ-Prep (sodium biphosphate / sodium phosphate) and burosumab

CONTRAINDICATED: Concomitant use of burosumab with oral phosphate and/or active vitamin D analogs may increase the risk of hyperphosphatemia and hypervitaminosis D due to additive pharmacologic effects. Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis.

MANAGEMENT: Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment. Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment. Some authorities advise that, if necessary, vitamin D replacement or supplementation with inactive forms of vitamin D may be started or continued as per local guidelines and under serum calcium and phosphate monitoring.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2018) "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical

Drug and food interactions

Moderate

sodium biphosphate food

Applies to: Fleet EZ-Prep (sodium biphosphate / sodium phosphate)

ADJUST DOSING INTERVAL: Bowel cleansing products can increase the gastrointestinal transit rate. Oral medications administered within one hour of the start of administration of the bowel cleansing solution may be flushed from the gastrointestinal tract and not properly absorbed.

MANAGEMENT: Patients should be advised that absorption of oral medications may be impaired during bowel cleansing treatment. Oral medications (e.g., anticonvulsants, oral contraceptives, antidiabetic agents, antibiotics) should not be administered during and within one hour of starting bowel cleansing treatment whenever possible. However, if concomitant use cannot be avoided, monitoring for reduced therapeutic effects may be advisable.

References (2)
  1. "Product Information. Golytely (polyethylene glycol 3350 with electrolytes)." Braintree
  2. (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer